Abstract 937
Background
The prognosis of type 4 or large type 3-gastric cancer is extremely poor. Despite various perioperative adjuvant therapies; as JCOG0501, peritoneal recurrence is still difficult to control. Since the clinical efficacy of chemo-radiotherapy was suggested for the treatment of advanced gastric cancer, chemo-radiotherapy is a promising strategy for curatively resectable type 4 or large type 3-gastric cancer. This multicenter, phase II study evaluated the efficacy and safety of radiotherapy combined with S-1 plus cisplatin for this target.
Methods
Eligibility criteria included pathologically confirmed gastric adenocarcinoma with macroscopically type 4 or large type 3, without peritoneal or distant metastases. Patients received preoperative chemo-radiotherapy with S-1 80 mg/m2/day from Day 1 to 14 and cisplatin 60 mg/m2 on Day 1, and radiotherapy at a total dose of 40 Gy in 20 fractions was delivered for 4 weeks, followed by D2 gastrectomy, and received S-1 monotherapy for one year postoperatively. The primary endpoint was the pathological complete response rate (% protocol completion). Secondary endpoints were safety, overall survival, and the response rate (RR). The sample size was calculated to be 30 cases, under the hypothesis of expected % pathological complete response rate of 15% and threshold pathological complete response rate of 2% with one-sided testing at the 10% significance level and power of 90%.
Results
From November 2012 to April 2018, 20 patients were enrolled. A median age of 20 patients was 67 years. Nineteen patients had protocol operation, and two of them showed pathological complete response (10.5%; 95% confidence interval 1.3–33.1%, p < 0.001). During preoperative chemotherapy, grade 3/4 neutropenia occurred in 25%, and grade 3/4 non-hematological adverse events occurred in 10%. The incidence of adverse events related to surgery was occurred in 31.6% patients. There were no treatment-related deaths. Follow-up for long-term survival is continuing. Notably the pathological RR (residual tumor < 2/3) was 100% (19/19).
Conclusions
Preoperative chemo-radiotherapy with S-1 plus CDDP is a safe and promising treatment for type 4 or large type 3 gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Osaka Gastointestinal Cancer Chemotherapy Study Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2840 - Effects of Aerobic and Resistance Exercise on Android:Gynoid Fat Ratio in Breast Cancer Survivors
Presenter: Christina Dieli-Conwright
Session: Poster Display session 2
Resources:
Abstract
869 - Impact of Education for Breast self examination in Rural Indian Women on Early Detection - results of POC study
Presenter: Sneha Parchuri
Session: Poster Display session 2
Resources:
Abstract
1951 - Breast cancer incidence and survival in renal transplant patients: 35-year experience
Presenter: Michalis Kontos
Session: Poster Display session 2
Resources:
Abstract
2017 - The changing landscape of breast cancer incidence after treatment for Hodgkin’s disease
Presenter: Amelia Benjamin
Session: Poster Display session 2
Resources:
Abstract
1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes
Presenter: Anniina Jääskeläinen
Session: Poster Display session 2
Resources:
Abstract
4650 - Effects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial
Presenter: Ana Joaquim
Session: Poster Display session 2
Resources:
Abstract
4962 - Study On the Socioeconomic and Clinical Factors Affecting the Proportion of Breast Conserving Surgery in Chinese Women Breast Cancer
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5451 - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
Presenter: Marco Giavarra
Session: Poster Display session 2
Resources:
Abstract
888 - The value of genetic counselling in breast cancer genetic testing and clinical management
Presenter: Vicki Kiesel
Session: Poster Display session 2
Resources:
Abstract
4005 - Elderly patients in the Japanese Breast Cancer Registry
Presenter: Masataka Sawaki
Session: Poster Display session 2
Resources:
Abstract